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Inability to die by apoptosis is one of the reasons for the deregulated growth of tumour cells and the frequently observed failure of
chemotherapy. In this study we thought to identify the common and functionally important characteristics responsible for the
apoptosis resistance of pancreatic tumour cells. We analysed cell surface expression level of death receptors CD95 and TRAIL-R1-4
as well as the expression profile of sixteen apoptosis-relevant proteins in five pancreatic carcinoma cell lines Capan1, Colo357,
PancTuI, Panc89 and Panc1. These data were evaluated in the context of sensitivity towards anti-CD95 and TRAIL-mediated
apoptosis. Here we report that except for resistant Panc1 cells, which only marginally expressed CD95, all other cell lines showed
comparable levels of CD95 and TRAIL receptors irrespectively of their apoptotic phenotype. Interestingly, we found that the
elevated expression of FLIP, Bcl-xL and IAP in parallel with a downregulation of FADD and Bid was common for the resistant cell
lines. Consequently, stable overexpression of XIAP, Bcl-xL or dominant negative FADD in sensitive cells significantly reduced the
death receptor mediated apoptosis while the overexpression of Bid rendered the resistant cells sensitive.
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CD95, TRAIL-R1 (tumour necrosis factor-related apoptosis indu-
cing ligand-receptor 1) and TRAIL-R2 are members of the TNF-
receptor family of transmembrane proteins that are capable of
inducing apoptosis (Wiley et al, 1995; Pitti et al, 1996; Pan et al,
1997; Peter et al, 1998). Following ligand binding, the receptors
oligomerize and the pro-apoptotic molecules TRADD, FADD and
FLICE/caspase-8 are recruited to their intracellular death domain
forming the ‘death-inducing signalling complex’ (DISC) (Kram-
mer, 1999). The subsequent events leading to apoptosis depend on
the specific cell type being challenged. In type I cells the bulk
induction of caspase-8 at the DISC leads to the direct activation of
the effector caspase 3. In type II cells only little amounts of
caspase-8 are activated at the DISC requiring the pro-apoptotic
mitochondrial amplification loop for efficient caspase-3 activation
(Scaffidi et al, 1998).
Resistance to apoptosis allows cancer cells to escape both the
host immune response and conventional radio- and chemotherapy
thus promoting tumour growth and progression. Several mechan-
isms have been proposed to negatively interfere with death
receptor signal transduction at either the receptor or mitochon-
drial level. For some tumour cells the absence of CD95 (Butler et al,
1998; Loro et al, 1999) or TRAIL-R1 and TRAIL-R2 (Ozoren et al,
2000; Nguyen et al, 2001) at the cell surface has been reported.
Additionally, two other TRAIL-receptors were discovered which
are unable to transduce the death signal and are believed to
negatively influence TRAIL-mediated apoptosis. TRAIL-R3 lacks
the entire cytoplasmic domain and was proposed to act as a decoy
receptor to inhibit TRAIL signalling (Degli-Esposti et al, 1997b;
Walczak et al, 1997). TRAIL-R4 lacks only the death domain and
its truncated cytoplasmic domain induces NF-kB (nuclear factor
kB), which can protect cells from apoptosis (Degli-Esposti et al,
1997a). Moreover, TRAIL-R1 and TRAIL-R2 both are able to
activate NF-kB (Schneider et al, 1997) and inhibition of NF-kB
augmented TRAIL-mediated apoptosis in haematopoietic (Jere-
mias et al, 1998) and pancreatic carcinoma cells (Trauzold et al,
2001). The activation of NF-kB has been shown to induce the
expression of apoptosis-protecting proteins like IAP (inhibitors of
apoptosis), TRAF2 and FLIP (Wang et al, 1998; Micheau et al,
2001). Constitutive downregulation of caspase-8 or the over-
expression of FLIP represent other protective mechanisms
preventing an efficient DISC formation (Irmler et al, 1997; Irisarri
et al, 2000; Eggert et al, 2001; Fulda et al, 2001). For type II cells it
has been shown that both overexpression of Bcl-xL (Hinz et al,
2000) and induction of PKC by PMA (Scaffidi et al, 1999) are able
to inhibit the cytochrome C release thus preventing the activation
of caspase-9 and caspase-3.
The majority of pancreatic adenocarcinoma cell lines is resistant
to CD95 and TRAIL-mediated apoptosis despite expressing the
corresponding death receptors at the cell surface (Ungefroren et al,
1998; Trauzold et al, 2001). Recently, we revealed an anti-apoptotic
role of constitutively overexpressed FAP-1 (Ungefroren et al, 2001)
and Bcl- xL (Hinz et al, 2000) in these cells. Moreover, we reported
the existence of another, inducible resistance-mechanism operat-
ing in these cells: upon ligand binding, both CD95 and TRAIL-R
activated protein kinase C (PKC) which protected pancreatic
tumour cells from apoptosis by preventing the loss of mitochon-
drial membrane potential and cytochrome C release as well as by
activation of NF-kB (Trauzold et al, 2001). Received 18 March 2003; revised 15 July 2003; accepted 23 July 2003
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cancer types with an extremely poor prognosis, it is crucial to
reveal common characteristics of pancreatic tumour cells in order
to develop new therapeutic strategies. Thus, we determined the
expression levels of several apoptosis-relevant proteins in a total of
five pancreatic tumour cell lines showing different potential to
undergo apoptosis, and we functionally analysed these data in the
context of sensitivity to anti-CD95- or TRAIL-induced cell death.
MATERIAL AND METHODS
Cell lines and culture conditions
Human pancreatic adenocarcinoma cell lines Capan1, Colo357,
PancTuI, Panc89, Panc1, and their suppliers have been described
previously (Sipos et al, 2003). All cells were cultured in RPMI 1640
supplemented with 10% FCS, 2mM glutamine and 1mM sodium
pyruvate. Retrovirally transduced cells expressing Bcl-xL and Bid
as well as the corresponding vector controls received puromycin
(2.5mgml
 1, Sigma, Deisenhofen, Germany) in addition. Colo357
cells over-expressing dominant negative FADD or transduced with
an empty vector were cultivated in the presence of G418
(600mgml
 1). Capan1/XIAP and Capan1/pcDNA3-transfectants
were grown in medium supplemented with 400mgml
 1 of G418.
For induction of apoptosis, agonistic monoclonal anti-CD95-
antibodies clone CH11 (100ngml
 1; Coulter Immunotech, Ham-
burg, Germany) or recombinant TRAIL (100ngml
 1;R & D
Systems GmbH, Wiesbaden, Germany) was added to the culture
medium for 24h.
Expression vectors
Construction of the retroviral Bcl-xL expression vector was
described in detail earlier (Hinz et al, 2000). A cDNA encoding
human Bid was generated by RT–PCR using total RNA from
Colo357 cells, Pfu polymerase (Stratagene, Heidelberg, Germany)
and primers Bid-forward (50-ACCATGGACTGTGAGGTCAA-
CAACG-30, start codon underlined) and Bid-reverse (50-
TGGAACTGTCCGTTCAGTCCATCC-30, stop codon underlined).
The resulting fragment was inserted in sense orientation into the
SnaBI site of the retroviral vector pBABE-puro. The correct
orientation and the identity with the published nucleotide
sequence were verified by sequencing. The cDNA for dominant
negative (DN) FADD (clone AU1-NFD4, kindly provided by Dr. C.
Vincenz, University of Michigan, Ann Arbor, USA) was released
from pcDNA3 (Invitrogen, Karlsruhe, Germany) with HindIII and
XhoI followed by polishment of both ends with Klenow fragment
and subcloning into the PmeI site of the retroviral vector
TJBA5bMolink-neo (Howard et al, 2000). These constructs were
co-transfected into 293T producer cells along with retroviral
packaging vectors as described previously (Howard et al, 2000).
Retroviral particles were used for transduction of Colo357 (Bcl-xL,
DN-FADD) or PancTuI and Panc89 (Bid) cells as described before
(Hinz et al, 2000).
The XIAP c-DNA in pcDNA3 was a kind gift from Dr. K.
Pfizenmaier (Inst. F. Zellbiologic and Immunologic, Stuttgart,
Germany) and was transfected in the presence of LipofectAMIN
2000 (20mgml
 1, Invitrogen Corp., Eggenstein, Germany) into
Capan1 cells.
JAM-Assay
The JAM assay was performed as previously described (Unge-
froren et al, 1998). The percentage of the target cell viability
measured as percentage of high molecular weight DNA retained on
glass fiber filters was calculated as: % viability¼(E/S)   100,
where E (experimental) is cpm of retained DNA in the presence of
apoptosis-inducing agent under study and S (spontaneous) is cpm
of retained DNA of untreated control cells.
FACS (fluorescence activated cell sorting) analysis
For detection of cell-surface expression of death receptors, 4 10
5
EDTA-released cells obtained from monolayer cultures were
incubated with anti-TRAIL-R1-4 (kindly provided by Dr. Henning
Walczak, German Center for Cancer Research, Heidelberg,
Germany) or anti-CD95 (APO1-3, Alexis Biochemicals, Gru ¨nberg,
Germany) mouse mabs (1:100 in PBS/1% BSA) for 1h at 41C,
washed twice in ice-cold PBS containing 0.05% sodium azide (PBS/
azide) and incubated with anti-mouse biotin-conjugated (for
TRAIL-receptors) and with FITC-conjugated anti-mouse second-
ary antibodies (for CD95) for additional 1h at 41C in the dark.
After two further washes with PBS/azide, cells were re-suspended
in 300ml 1% paraformaldehyde in PBS prior to FACS analysis (for
CD95) or incubated with phycoerythrin-conjugated streptavidin
(for TRAIL-receptors), washed again twice as before and re-
suspended in 300ml 1% paraformaldehyde in PBS.
Flow cytometric analysis was carried out using a FACScan
(Becton Dickinson, Heidelberg, Germany) and analysed with the
Cell Quest program. At least 10000 cells were examined for each
determination with the window set to exclude cellular debris and
non-viable cells.
As control the fluorescence of cells incubated with appropriate
isotype matched antibodies followed by labelling with the
corresponding secondary antibodies was measured.
Western blot
For detection of the expression of apoptosis relevant proteins, cells
were grown to 70% confluence and lysed in RIPA buffer. The
lysates (30mg total protein per lane) were separated by SDS–
PAGE, blotted onto PVDF-membrane and incubated with the
appropriate primary antibodies followed by incubation with the
HRP-conjugated secondary antibody (Amersham Pharmacia
Biotech, Freiburg, Germany). Antigen visualization was performed
by enhanced chemiluminescence (ECL-kit, Amersham Pharmacia
Biotech). Primary antibodies used and their suppliers were as
follows: anti-caspase-8 and anti-caspase-9 (StressGen Biotechnol-
ogy, Canada), anti-caspase-3, anti-caspase-2, anti-caspase-7, anti-
FADD, anti-Bcl-xL, anti-Apaf-1, anti-BAD (Transduction Labora-
tories/BD, Heidelberg, Germany), anti-Bfl-1 (Santa Cruz Biotech-
nology, Santa Cruz, CA), anti-Bid, anti-c-FLIP, anti-XIAP, anti-c-
IAP2 and anti-Survivin (R&D Systems, Wiesbaden, Germany),
anti-Smac/DIABLO (Biocarta, Hamburg, Germany) and anti-Bax
(PharMingen, Hamburg, Germany).
RESULTS
CD95- and TRAIL-mediated apoptosis and the cell surface
expression of death receptors on pancreatic adenocarcinoma cell
lines.
In this report we determined in parallel the sensitivities of five
pancreatic carcinoma cell lines, Capan1, Colo357, PancTuI, Panc89
and Panc1 to anti-CD95- and TRAIL-mediated apoptosis in the
context of the cell surface expression of the corresponding
receptors. Here we used a concentration of 100ngml
 1 of either
CH11 or TRAIL because the recently published dose response
curves for both stimuli and cell lines Colo357, PancTuI and Panc1
showed no significant further apoptosis at concentrations up to
1000ngml
 1 (Hinz et al, 2000). Table 1 shows that three cell lines
were either almost completely (PancTuI and Panc1) or highly
(Panc89) resistant to CD95-mediated apoptosis. Two other cell
lines Colo357 and Capan1 were moderate and highly sensitive to
anti-CD95-treatment, respectively.
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anti-CD95 since only the cell line PancTuI remained highly
refractory (13.3% apoptosis) to TRAIL treatment whereas 24.6% of
Panc1 cells, 35.6% of Panc89 cells, 68.1% of Colo357 cells and
86.3% of Capan1 cells died after 24h exposition to TRAIL.
Despite the differences in sensitivity of Capan1 and Colo357
cells to anti-CD95 and TRAIL we classified these cell lines as rather
sensitive in contrast to PancTuI, Panc89 and Panc1 cells, which
were regarded as mostly resistant.
Since the susceptibility of cells to anti-CD95 and TRAIL could
reflect the different amount of corresponding receptors, we
analysed the expression of CD95 and TRAIL-R1-4 at the cell
surface of all five cell lines. Figure 1 shows that Capan1, Colo357
and PancTuI cells expressed comparable amounts of CD95 whereas
the amount of CD95 on plasma membrane of Panc89 cells was
slightly lower and on Panc1 cells almost undetectable. In contrary,
TRAIL-R1 and TRAIL-R2 were highly expressed on all cells and
even stronger on the most resistant PancTuI than on most
sensitive Capan1 cells.
Recently, it has been shown that the sensitivity to TRAIL may be
modulated by the expression of TRAIL-R3 and TRAIL-R4. For
both receptors a protective role in TRAIL-mediated apoptosis has
been postulated. Appropriate FACS analysis revealed no detectable
levels of TRAIL-R3 on either cell line and no (Capan1, Colo357 and
Panc1) or almost no detectable levels of TRAIL-R4 on PancTuI and
Panc89 cells (Figure 1).
These data strongly suggest that the block in CD95- (except for
Panc1 cells) and TRAIL-mediated apoptosis is located downstream
of the receptor level.
Table 1 Sensitivity of pancreatic tumour cells to CD95-mediated
apoptosis.
Cell line CH11 viability (%) TRAIL viability (%)
Capan1 32.870.8 13.771.4
Colo357 66.671.5 31.970.7
PancTuI 95.774.1 86.774.0
Panc89 86.772.4 64.472.7
Panc1 98.670.3 75.473.0
Cells were treated for 24h with agonistic anti-CD95 antibody CH11 or with
recombinant TRAIL. The viability of the cells was determined by JAM-Assay. Data
represent means 7 SD of three independent experiments performed 6-fold each
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Figure 1 Flow cytometric analysis of cell surface expression of CD95, TRAIL-R1-4 on pancreatic tumour cells. Bold lines: specific monoclonal antibodies
as indicated in the figure, thin lines: isotype control monoclonal antibodies. Shown are representative results of one out of three experiments performed.
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adenocarinoma cells
Since sensitivity to death receptor-induced apoptosis in pancreatic
tumour cell lines did obviously not correlate with cell surface
expression of death receptors, we systematically analysed the
expression of a set of intracellular proteins known to be involved
in transmission or inhibition of the death signal.
Recently, it has been reported that deficiency in caspase-8
expression was a key determinant of apoptosis sensitivity of
malignant brain tumours and melanoma (Fulda et al, 2001). In
contrast, sensitive as well as resistant pancreatic tumour cells all
expressed comparable and rather high amounts of caspase-8
(Figure 2). Similarly, expression of caspase-9, -3, -7, and -2 was
readily detectable in all cells although the levels of caspase-8, -9,
and -7 were elevated in the most sensitive Capan1 cells (Figure 2).
We found that the DISC interacting protein FADD was clearly
down-regulated in resistant cells (Figure 3). In addition, compared
to Capan1, these cells expressed elevated levels of c-FLIP.
Since it was shown (Hinz et al, 2000; Trauzold et al, 2001) that
pancreatic tumour cell lines behave like type II cells in both, CD95-
and TRAIL-mediated apoptosis, we did not only analyse the
expression levels of caspases and DISC components, but also of
proteins which participate in the mitochondrial apoptosis pathway
(Figure 4). The expression pattern of two of them, Bid and Bcl-xL
correlated well with the sensitivity of cell lines to TRAIL and anti-
CD95-treatment. The pro-apoptotic Bid protein was clearly down-
regulated in resistant cells in comparison to Capan1. But
interestingly, moderately sensitive Colo357 cells also showed a
strong down-regulation of Bid expression. In contrast, the anti-
apoptotic Bcl-xL was up-regulated in all resistant cells. Only
recently Werner et al. demonstrated that the novel anti-apoptotic
member of the Bcl-2 family Bfl-1 sequesters truncated Bid thereby
inhibiting the mitochondrial pathway of apoptosis (Werner et al,
2002). Therefore, we additionally analysed the expression of Bfl-1.
We found Bfl-1 to be clearly overexpressed in Capan1, Panc89 and
PancTuI whereas Panc1 cells showed only very little and Colo357
cells no expression of Bfl-1 (Figure 4).
During apoptosis, the Smac/DIABLO protein is released from
mitochondria along with cytochrome C, binds to and inhibits IAPs
and promotes cytochrome C-dependent caspase-9 activation (Du
et al, 2000). Analysis of Smac/DIABLO expression in pancreatic
tumour cells surprisingly showed a reverse correlation with the
sensitivity of these cells to anti-CD95 or TRAIL (Figure 4).
Since particular differences in the expression of caspases
between sensitive and resistant cell lines were not observed, we
also analysed the expression of several members of the IAP
(inhibitors of apoptosis) family (reviewed by Deveraux and Reed,
1999). These proteins are direct inhibitors of caspases and thus
play an apoptosis-protective role if up-regulated.
Here we show that the most resistant PancTuI cells expressed
strongly elevated levels of c-IAP2, XIAP and Survivin (Figure 5).
Similarly, Panc1 cells which were also resistant to both, anti-CD95
and TRAIL, expressed more of IAP-proteins (XIAP, Survivin) than
the sensitive Capan1 and Colo357 cells. Panc89 cells, which were
resistant against anti-CD95 but only moderately resistant to
TRAIL, expressed clearly less of all IAPs than PancTuI and Panc1
cells but still more than Capan1 or Colo357.
Functional verification of the expression data
The Western blot analysis revealed over-expression of Bcl-xL and
XIAP and down-regulation of Bid as well as FADD in resistant
cells. To verify the putative role of these proteins in the apoptosis
deficiency of the respective pancreatic tumour cells, we con-
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Capan1
Colo357
PancTuI
Panc89
Panc1
Caspase-3
Caspase-9
Caspase-7
Caspase-2
-actin
−32
−46
−35
−48
−55/54
mw(kDa)
-actin
-actin
-actin
-actin
Figure 2 Expression of caspases in pancreatic adenocarcinoma cell lines.
30mg of whole cell lysates from Capan1-, Colo357-, PancTuI-, Panc89- and
Panc1 cells were separated in 12% SDS–PAGE and analysed by Western
blot using anti-caspase-8, anti-caspase-3, anti-caspase-9, anti-caspase-2, and
anti-caspase-7 antibodies. Equal loading of the gels was verified by the
determination of b-actin expression. Data are representative of at least
three independent experiments.
c-FLIP
Capan 1
Colo357
PancTuI
Panc89
Panc1
FADD
-actin
-actin
mw(kDa)
−24
−55
Figure 3 Expression of DISC interacting proteins FADD and FLIP in
pancreatic tumour cells. Equal amounts of whole cell lysates (30mg) from
each cell line were separated in 4–12% gradient gels and blotted onto
PVDF membrane. Subsequently, the expression of FADD and FLIP was
detected using specific antibodies. Equal loading of slots was verified by
determination of b-actin expression. Data are representative of at least
three independent experiments.
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gene products found down-regulated, or over-expressing domi-
nant-negative gene products found to be up-regulated in
pancreatic tumour cells. Recombinant Colo357-Bcl-xL transduc-
tants strongly over-expressed Bcl-xL protein (Figure 6A upper
panel). These cells showed highly enhanced viability after anti-
CD95 or TRAIL treatment compared to apoptosis-sensitive
Colo357 wildtype (WT) cells.
Similarly, an over-expression of XIAP in the most sensitive
pancreatic tumour cell line Capan1 dramatically increased their
viability after treatment with both death-inducing ligands
(Figure 6B).
Since Colo357 as well as Capan1 cells expressed high amounts of
FADD, and all resistant cells showed strongly reduced levels of
FADD, we investigated if we could lower the sensitivity of Colo357
cells to anti-CD95 and/or TRAIL by the expression of a dominant
negative FADD protein. This mutant protein carries a deletion of
the N-terminal portion of the protein known as the death effector
domain (DED) and thus attenuates its ability to induce cell death
(Chinnaiyan et al, 1995). As shown in Figure 6C Colo357 cells
transduced with an expression vector coding for the dominant
negative FADD mutant (expressing the truncated tFADD) were
markedly more resistant to anti-CD95 and TRAIL than wildtype
Colo357 or cells transduced with an empty vector.
Similarly, the down-regulation of Bid, also plays a role in
establishing the resistant phenotype, since the reconstitution of the
high Bid expression in PancTuI and Panc89 cells led to
sensitisation of both cell lines to CD95- and TRAIL-mediated
apoptosis (Figure 6D).
DISCUSSION
In this study we identified several changes in the expression
pattern of apoptosis-relevant proteins in mostly resistant versus
rather sensitive pancreatic tumour cells. We observed a concerted
down-regulation of several pro-apoptotic proteins in conjunction
with the up-regulation of anti-apoptotic proteins in resistant cells.
We showed that all pancreatic tumour cells expressed TRAIL-R1
and TRAIL-R2 irrespective of their sensitivity to recombinant
TRAIL. Moreover, we could not detect TRAIL-R3 on the surface of
Capan1, Colo357, PancTuI and Panc1 cells and we found only
extremely low level of this receptor on Panc89 cells. Similarly,
TRAIL-R4 was undetectable on Capan1, Colo357 and Panc89 cells
and almost undetectable on PancTuI and Panc89 cells. Thus in the
case of the TRAIL-mediated apoptosis the resistance seemed to be
achieved downstream of the receptor level. In the case of CD95 we
found some heterogeneity in the CD95-expression on the cell
surface of apoptosis-resistant cells. Panc1 cells expressed ex-
treamly little CD95 whereas the expression of CD95 on PancTuI
cells was similar and on Panc89 cells slightly lower compared to
the sensitive Capan1 or Colo357 cells. The observed down-
regulation of CD95 may indeed play an important role in biological
Bid
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 -actin
 
 
 
 
 
Bfl-1
 
−20
mw(kDa)
−23
−23
−26
−21
−130
−25
-actin
-actin
-actin
-actin
-actin
-actin
Figure 4 Expression levels of proteins involved in the mitochondrial
apoptosis pathway in pancreatic adenocarcinoma cells. 30mg of whole cell
lysates were analysed by Western blot analysis for constitutive expression
of Bid, Bfl-1, Bad, Bcl-xL, Bax, Smac/DIABLO and Apaf-1. Equal gel loading
was verified by assessing b-actin levels. Data are representative of three
independent experiments.
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Figure 5 Immunoblot detection of proteins of the IAP-family in
pancreatic tumour cells. Protein extracts (30mg) of pancreatic tumour
cells were separated by 12% SDS–PAGE, blotted onto PVDF membranes
and the expression of c-IAP2, XIAP and Survivin was analysed using specific
antibodies. In parallel, b-actin expression was determined in all lanes.
Representative results of three independent experiments are shown.
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et al. (2002) reported a reduced membranous CD95 staining in
tissue sections of invasive ductal adenocarcinomas compared to
normal pancreatic tissue.
The results presented here suggest that tumour cells acquired
resistance against anti-CD95 and TRAIL by modifying the
expression of several apoptosis-relevant proteins beginning with
those acting already at the receptor level. Here, additionally to the
perturbations of the receptor expression, proteins interfering with
the DISC formation are involved. Thus we found strongly
diminished amounts of FADD in resistant cells compared to the
sensitive ones. Since FADD is an adaptor protein responsible for
the recruitment of pro-caspase-8 to the death receptor, its down-
regulation will affect the DISC formation and in consequence the
apoptotic behaviour of the cells. This hypothesis was proven by
transfection of Colo357 cells with a dominant negative FADD
construct (Figure 6C). As an additional mechanism of apoptosis
inhibition serves the increased synthesis of FLIP observed mostly
pronounced in Panc1, and to a lesser extend in Colo357 and
PancTuI cells. This in conjunction with reduced FADD expression
clearly contributes to the acquired apoptosis resistance of
pancreatic tumour cells. The importance of the balance between
anti-apoptotic and pro-apoptotic molecules for the apoptotic
outcome is supported by the observation that Colo357 cells being
less sensitive than Capan1 express slightly higher amount of
FADD, which may than be counteracted by an increased
expression of FLIP.
In contrast to brain tumour cells the expression of caspases is
not limiting for apoptosis of pancreatic tumour cells and does not
correlate with the sensitivity status of the cells under study expect
for most sensitive Capan 1 cells, which expressed elevated levels of
caspase-8, -9, and -7. Interestingly, Panc1- or Panc89 cells, both
classified as mostly resistant, expressed slightly elevated levels of
caspase-3 or caspase-9, respectively.
Pancreatic carcinoma cells are regarded as type II cells in which
only small amounts of active caspase-8 are generated at the DISC
and a mitochondrial amplification loop is necessary for proper
apoptosis induction (Hinz et al, 2000; Trauzold et al, 2001;
Ungefroren et al, 2001).
Following caspase-8-activation the full length Bid, a small pro-
apoptotic cytosolic protein, is cleaved and the p15 tBid fragment
targets mitochondria eventually leading to the disruption of the
mitochondrial transmembrane potential Dcm and cytochrome C
release (reviewed by Yin, 2000). Cytochrome C associates with
Apaf-1 and induces its oligomerization. Oligomerized Apaf-1 binds
the pro-caspase-9 forming the so-called apoptosome, which
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caspase-9 cleaves and activates the effector caspases-3, -6 and -7,
which in turn, by cleaving their substrates, complete the apoptotic
cell death. Along with cytochrome C the Smac/DIABLO protein is
released into the cytoplasm and binds to IAPs, thereby inhibiting
them, and consequently allowing the caspases to complete the
apoptotic process (Srinivasula et al, 2000). Bcl-xL is an anti-
apoptotic protein, which similarly to Bcl-2 prevents the mitochon-
drial membrane disruption (reviewed by Korsmeyer, 1999). It has
been shown that Bcl-xL can protect cells from apoptosis induced by
death receptors and chemotherapeutic agents. We show here that
Bid is down-regulated and Bcl-xL is up-regulated in resistant
pancreatic tumour cell lines. Such perturbation in the expression
of both proteins are likely to contribute to the resistant phenotype
since these cells require the mitochondrial amplification loop for
efficient induction of anti-CD95 and TRAIL-induced apoptosis. In
fact, we could recently demonstrate a protective role of Bcl-xL in
CD95- and TRAIL-R-mediated apoptosis (Hinz et al, 2000). Data of
the present work concerning the role of Bid down-regulation
support this hypothesis, since stable over-expression of Bid in
resistant PancTuI and Panc89 cells converted both into highly
sensitive cell lines. The observed strong down regulation of Bid in
sensitive Colo357 cells is accompanied with nearly absence of the
expression of Bcl-xL as well as Bfl-1. Bfl-1 is a protein of the Bcl-2
family, which has recently been shown to bind and inactivate
truncated Bid (Werner et al, 2002). Thus no or very low expression
of Bfl-1 in Colo357 cells in conjunction with very little amounts of
Bcl-xL may account for the observed sensitivity of these cells to
CD95- and TRAIL-mediated apoptosis. Unexpectedly, the most
sensitive Capan1 cells expressed the highest level of Bfl-1. This
must be considered in the context of the very high amount of Bid
and strongly diminished expression of Bcl-xL. In addition, the high
expression of caspases and FADD in combination with a low
expression of FLIP may contribute to the high sensitivity of
Capan1 cells towards CD95- and TRAIL-mediated apoptosis.
An additional level known to influence the apoptosis sensitivity
is represented by the regulation of caspase activation. Members of
IAPs family e.g. c-IAP1, c-IAP2, XIAP and Survivin all bind to and
potently inhibit caspases-3, -7 and -9. XIAP has been shown to be
ubiquitously expressed in adult and fetal tissues (Liston et al,
1996), whereas c-IAP1 and c-IAP2 expression is more hetero-
geneous being abundant in kidney, liver, lung and small intestine
and low in tissues of the central nervous system, pancreas,
peripheral leukocytes and the mammary gland (Young et al, 1999).
The constitutive expression of Survivin has been reported to be
restricted to fetal tissues, but interestingly, a high level of
expression was observed in several human cancers (Ambrosini
et al, 1997). The analysis of its promoter region and in vitro data
suggested that Survivin is a G2/M associated protein involved in
the control of proliferation. Analysis of the expression of IAPs in
pancreatic tumour cells revealed the increased levels of XIAP and
Survivin in all three resistant cell lines and, in particular, a very
strong overexpression of c-IAP2 in the most resistant PancTuI
cells. Both mostly sensitive cell lines showed reduced expression of
IAPs with the lowest levels of all IAPs in Capan1 cells.
The results presented here reveal multiple changes of the
expression of apoptosis-relevant proteins in resistant pancreatic
adenocarcinoma cell lines. Concurring observed decreased levels
of FADD, elevated levels of FLIP, and in one case down-regulation
of the CD95 receptor all suggest that protection from death
receptor mediated apoptosis occurs at least partially already at the
receptor level by inhibition of DISC formation. Additionally, a
decrease of Bid and an increase of Bcl-xL expression impede the
mitochondrial amplification loop essential for apoptosis in type II
cells. The expression of caspase inhibitors XIAP, c-IAP2 and
Survivin provides additional protection. The most resistant
PancTuI cells accumulated more changes in the expression of
apoptosis relevant proteins than less resistant Panc89 or Panc1.
Correspondingly, the expression pattern of these proteins in
Colo357 and Capan1 cells reflects the differences in the apoptosis
susceptibility. In conclusion, concerted multiple changes rather
than single or few perturbations of death receptor signalling are
likely to be responsible for the resistance of pancreatic adeno-
carcinoma cells to CD95- and TRAIL-R-mediated apoptosis.
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